CTXR furnishes press release reporting third-quarter fiscal 2025 results

Rhea-AI Filing Summary

Citius Pharmaceuticals reported that it has issued a press release announcing its results of operations for the third quarter of fiscal 2025. The company states the press release is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference into the report. The filing explains that the information in Item 2.02, including Exhibit 99.1, is furnished rather than filed for purposes of the Exchange Act and therefore is not subject to the same liabilities as a filed disclosure.

The Form 8-K lists the furnished exhibit and an interactive cover page document, and it is signed on behalf of the registrant by the chairman and chief executive officer. No financial line items, operating metrics, or forward-looking guidance appear within the 8-K text itself; readers must refer to Exhibit 99.1 for the underlying results.

Positive

• Press release furnished as Exhibit 99.1, providing investors with announced third-quarter fiscal 2025 results
• Formal 8-K disclosure and CEO signature indicate timely compliance with reporting obligations

Negative

• The 8-K does not include any financial metrics or operating details; underlying numbers are only in the furnished press release
• Information is furnished, not filed, which limits certain legal liabilities and may affect how the disclosure is treated for incorporation in future filings

Insights

Securities Analyst

TL;DR: Routine disclosure furnishing a press release with quarter results; the filing itself provides no financial detail.

This 8-K is procedural: it furnishes a press release containing third-quarter fiscal 2025 operating results as Exhibit 99.1 but does not present operating metrics or financial statements within the filing text. Because the release is expressly furnished rather than filed, its legal treatment differs and the 8-K itself offers limited new information for valuation or credit analysis. Investors and analysts must review Exhibit 99.1 to assess revenue, profit, cash flow, or reserve changes and their materiality.

Corporate Governance Expert

TL;DR: Governance disclosure is compliant and transparent but legally limited by the furnished status of the press release.

The registrant followed Form 8-K protocol by furnishing a press release and identifying exhibits and cover page files. The filing includes an authorized signature from the chairman and CEO, indicating proper execution. The statement that the item is furnished rather than filed is standard practice to delineate legal exposure; it preserves disclosure while limiting incorporation-by-reference liabilities. This filing is administrative in nature and does not on its own change governance or reporting obligations.

false 0001506251 0001506251 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 12, 2025

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

001-38174		27-3425913
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		CTXR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, we issued a press release announcing our results of operations for the third quarter of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated August 12, 2025.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CITIUS PHARMACEUTICALS, INC.
Date: August 12, 2025	/s/ Leonard Mazur
	Leonard Mazur
	Chairman and Chief Executive Officer

2

FAQ

What did Citius Pharmaceuticals (CTXR) disclose in this 8-K?

The company disclosed that it has issued a press release announcing its third-quarter fiscal 2025 results, furnished as Exhibit 99.1 to the Form 8-K.

Is the press release in this filing considered "filed" with the SEC?

No. The filing explicitly states the information in Item 2.02, including Exhibit 99.1, is furnished rather than filed and is not subject to the same liabilities as a filed disclosure.

Where can I find the actual financial figures for CTXR's third quarter fiscal 2025?

The underlying financial figures are contained in the press release furnished as Exhibit 99.1; the Form 8-K text itself does not include line-item financial data.

Who signed the Form 8-K for Citius Pharmaceuticals (CTXR)?

The Form 8-K was signed on behalf of the registrant by Leonard Mazur, Chairman and Chief Executive Officer.

What exhibits are listed in this 8-K?

The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (interactive cover page data file).